ROME III criteria

ROME III criteria

Criteria which are used to diagnose irritable bowel syndrome.
Symptoms of recurrent abdominal pain or discomfort and a marked change in bowel habit for at least 6 months, with symptoms on at least 3 days for at least three months, and 2 or more of the following:
• Pain is relieved by a bowel movement;
• Pain onset linked to a change in frequency of stool;
• Pain onset linked to a change in appearance of stool.
References in periodicals archive ?
Prevalence and risk factors for functional bowel disorders in South China: A population based study using the Rome III criteria. Neurogastroenterol Motil 2016; 29(1): 128-37.
Based on the survey data of the participants, those with functional constipation according to the Rome III criteria were determined, and participants were included in the study without any additional systemic disease or organic bowel disease (Crohn disease, ulcerative colitis, etc.), or IBS.
Patients were diagnosed with IBS according to Rome III criteria.13 They were all screened for psychiatric or organic bowel diseases for the sake of precise diagnosis.
A questionnaire was divided into three parts: collecting demographic data, determining the Rome III criteria for functional constipation whether it was met or not, and questioning hygiene-dietary habits that might influence the onset or persistence of constipation.
IBS patients were diagnosed using Rome III criteria. [2] Patients who consented to participate were then interviewed to collect relevant data.
Prevalence of irritable bowel syndrome in Chinese college and university students assessed using Rome III criteria. World J Gastroenterol 2010; 16: 4221-6.
By definition non-ulcer dyspepsia is epigastric symptom in the absence of structural lesion.1 According to Rome III criteria non-ulcer dyspepsia is one of the three symptoms for last three months with onset at least six months previously.
The Rome III criteria [1, 2] have been widely applied for the diagnosis of functional gastrointestinal disorders, including FC, and have been commonly used in clinical research.
ROME III criteria was used for the diagnosis of IBS and to assess GAD, a 7-item Generalized Anxiety Disorder (GAD-7) scale was used.
T3MPO-1 was the company's 12-week, double-blind, placebo-controlled, multi-centre, randomized trial with a four-week, randomized withdrawal period conducted in a total of 610 patients meeting the ROME III criteria for the diagnosis of IBS-C.
In particular, more than 40% of patients who visit primary clinics and tertiary hospitals in South Korea have been diagnosed as having FD according to a survey using the Rome III criteria [3].
Urinary symptoms were evaluated by OABSS and constipation was evaluated by the Rome III criteria. The OABSS was developed to assess the presence and severity of OAB symptoms as a self-administered four-item questionnaire (score: 0 to 15) [17].